Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Milnacipran

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Milnacipran. Displaying page 1 of 1.
    EudraCT Number: 2004-004249-16 Sponsor Protocol Number: F02207GE204 Start Date*: 2005-02-02
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY
    Medical condition: Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, widespread tenderness and fatigue. The disorder is well defined in the USA, where the current diagnosis of FMS i...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003137-40 Sponsor Protocol Number: F02207GE302 Start Date*: 2015-09-28
    Sponsor Name:Pierre Fabre Medicament
    Full Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome.
    Medical condition: Fibromyalgia, also known as FMS, is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population Fibromyalgia is associated with a reduced threshold for pain, generally i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002302-43 Sponsor Protocol Number: CHDR1209 Start Date*: 2012-06-08
    Sponsor Name:Dr. Reddy's Laboratories Ltd.
    Full Title: A study to investigate the analgesic effects of buprenorphine and milnacipram in healthy volunteers.
    Medical condition: Pain therapeutics, neuropathic pain, nociceptive pain, synergism between opioids and TCA.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    14.1 10018065 - General disorders and administration site conditions 10066714 Acute pain LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001230-41 Sponsor Protocol Number: F02207GE304 Start Date*: 2006-08-17
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME
    Medical condition: Fibromyalgia syndrome (FMS) is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population. Fibromyalgia is associated with a reduced threshold for pain, generally identi...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) GB (Prematurely Ended) DK (Prematurely Ended) PT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003658-47 Sponsor Protocol Number: F02207 GE 3 03 Start Date*: 2006-11-21
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002731-28 Sponsor Protocol Number: P12-01/BP1.4979 Start Date*: 2013-03-01
    Sponsor Name:Bioprojet
    Full Title: Randomized placebo controlled trial assessing the efficacy and safety of BP1.4979 in smoking cessation
    Medical condition: Smoking cessation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004869 10008374 Cessation of smoking LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001192-17 Sponsor Protocol Number: ITI-007-501 Start Date*: 2021-11-24
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BG (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001212-29 Sponsor Protocol Number: ITI-007-502 Start Date*: 2022-01-23
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005282-22 Sponsor Protocol Number: 42847922MDD2001 Start Date*: 2017-10-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004884-30 Sponsor Protocol Number: P13-04/BP1.4979 Start Date*: 2017-12-07
    Sponsor Name:BIOPROJET PHARMA
    Full Title: Randomized double blind parallel groups sequential, placebo controlled, trial assessing the efficacy and safety of BP1.4979 in Resteless Legs Syndrome (RLS).
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10058920 Restless legs syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 09:02:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA